An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for broader availability to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how policymakers view custom-mixed peptide therapies, which have drawn increasing interest from consumers seeking alternatives to traditional drugs. Scientists say peptide treatments could change approaches to resistant infections, though concerns about consistency persist. The committee's endorsement of four peptides clears a path for more widespread prescribing, even as skeptics warn of limited evidence. Market watchers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on some peptide candidates.